U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07160725) titled 'A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors' on Aug. 29.
Brief Summary: A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
Study Start Date: Oct. 28
Study Type: INTERVENTIONAL
Condition:
Solid Tumours
Intervention:
DRUG: BMS-986517
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bristol-Myers Squibb
Published by HT Digital Content Services with permission from Health Daily Digest....